Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Phase II study finds IL-2 fusion protein effective but toxic in patients with psoriasis

July 27, 1998

Antipsoriatic dihydrofolate reductase inhibitors available for licensing from BTG

July 22, 1998

Altana offer to license Solarase accepted by Hyal

July 21, 1998

Celgene cleared to market Thalomid in U.S.

July 20, 1998

First demonstration of efficacy for PDT in treating autoimmune disorders

July 17, 1998

Mylan announces copromotion agreement

July 15, 1998

Phase III trial of new foam formulation of clobetasol initiated

July 14, 1998

Dermatological agents in development at Galderma

July 10, 1998

Phase III study shows efficacy of becaplermin treatment for diabetic neuropathic ulcers

July 8, 1998

Dusa submits NDA for Levulan PDT of actinic keratoses

July 6, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.